Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Iovance Biotherapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 236
- +11 vs. Q3 2023
- Shares held
- 207.3M
- −5.29M (−2.5%) vs. Q3 2023
- Total value
- $1.69B
- +$718.0M (+74.2%) vs. Q3 2023
- New holders
- 47
- 87 more added
- Sold out
- 36
- 70 more reduced
3 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOVA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 293 | $1.19B |
| Q1 2026 | 286 | $943.8M |
| Q4 2025 | 263 | $713.7M |
| Q3 2025 | 253 | $462.3M |
| Q2 2025 | 255 | $379.3M |
| Q1 2025 | 303 | $798.9M |
| Q4 2024 | 302 | $1.79B |
| Q3 2024 | 286 | $2.21B |
| Q2 2024 | 295 | $1.86B |
| Q1 2024 | 273 | $3.22B |
| Q4 2023 | 236 | $1.69B |
| Q3 2023 | 228 | $970.0M |
| Q2 2023 | 219 | $1.44B |
| Q1 2023 | 230 | $1.25B |
| Q4 2022 | 218 | $1.11B |
| Q3 2022 | 242 | $1.48B |
| Q2 2022 | 238 | $1.75B |
| Q1 2022 | 248 | $2.60B |
| Q4 2021 | 246 | $2.96B |
| Q3 2021 | 244 | $3.88B |
| Q2 2021 | 234 | $4.22B |
| Q1 2021 | 252 | $4.98B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Iovance Biotherapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Invenomic Capital Management LP | 1,053,251 | $8.56M | 0.46% | +1,053,251 | New |
| Rhenman & Partners Asset Management AB | 1,116,818 | $9.08M | 0.91% | +166,818+17.6% | Added |
| Norges Bank | 1,120,457 | $9.11M | 0.00% | 00.0% | Unchanged |
| Rafferty Asset Management, LLC | 1,247,515 | $10.1M | 0.04% | −248,655−16.6% | Reduced |
| C WorldWide Group Holding A/S | 1,360,000 | $11.1M | 0.15% | 00.0% | Unchanged |
| Boxer Capital, LLC | 1,400,000 | $11.4M | 0.57% | −2,305,133−62.2% | Reduced |
| Susquehanna International Group, LLP | 1,598,930 | $13.0M | 0.02% | +353,893+28.4% | Added |
| Woodline Partners LP | 1,604,706 | $13.0M | 0.14% | +958,411+148.3% | Added |
| Candriam Luxembourg S.C.A. | 1,727,822 | $14.0M | 0.10% | −1,020,031−37.1% | Reduced |
| Charles Schwab Investment Management Inc | 1,747,023 | $14.2M | 0.00% | +54,490+3.2% | Added |
| 683 Capital Management, LLC | 1,750,000 | $14.2M | 1.42% | −300,000−14.6% | Reduced |
| Rice Hall James & Associates, LLC | 1,750,907 | $14.2M | 0.82% | +28,196+1.6% | Added |
| Deutsche Bank AG | 1,915,412 | $15.6M | 0.01% | +1,412,125+280.6% | Added |
| Hood River Capital Management LLC | 2,001,510 | $16.3M | 0.45% | +9,175+0.5% | Added |
| Palo Alto Investors LP | 2,106,792 | $17.1M | 1.54% | +2,106,792 | New |
| Long Focus Capital Management, LLC | 2,135,521 | $17.4M | 2.24% | −335,000−13.6% | Reduced |
| Northern Trust Corp | 2,182,877 | $17.7M | 0.00% | +189,698+9.5% | Added |
| Principal Financial Group Inc | 2,636,327 | $21.4M | 0.01% | −6,828−0.3% | Reduced |
| Credit Suisse AG | 2,814,316 | $22.9M | 0.02% | −29,153−1.0% | Reduced |
| JPMorgan Chase & Co | 2,839,667 | $23.1M | 0.00% | +93,311+3.4% | Added |
| Price T Rowe Associates Inc | 3,276,602 | $26.6M | 0.00% | −320,518−8.9% | Reduced |
| MPM Oncology Impact Management LP | 3,289,470 | $26.7M | 6.26% | +2,073+0.1% | Added |
| Dimensional Fund Advisors LP | 3,516,987 | $28.6M | 0.01% | −461,398−11.6% | Reduced |
| Goldman Sachs Group Inc | 3,681,560 | $29.9M | 0.01% | −82,078−2.2% | Reduced |
| Morgan Stanley | 3,715,545 | $30.2M | 0.00% | +1,233,420+49.7% | Added |
| Balyasny Asset Management LLC | 3,926,159 | $31.9M | 0.09% | −550,677−12.3% | Reduced |
| OrbiMed Advisors LLC | 4,707,458 | $38.3M | 0.77% | 00.0% | Unchanged |
| Artisan Partners Limited Partnership | 4,827,670 | $39.2M | 0.06% | −208,809−4.1% | Reduced |
| Geode Capital Management, LLC | 5,037,098 | $41.0M | 0.00% | +287,687+6.1% | Added |
| Pictet Asset Management Holding SA | 5,263,309 | $42.8M | 0.05% | −1,650,375−23.9% | Reduced |
| Avoro Capital Advisors LLC | 6,700,000 | $54.5M | 0.75% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 11,979,415 | $97.4M | 2.18% | +16,477+0.1% | Added |
| State Street Corp | 16,424,388 | $133.5M | 0.01% | −307,881−1.8% | Reduced |
| BlackRock Inc. | 19,071,756 | $155.1M | 0.00% | +695,327+3.8% | Added |
| MHR Fund Management LLC | 19,997,103 | $162.6M | 17.76% | 00.0% | Unchanged |
| Vanguard Group Inc | 22,812,820 | $185.5M | 0.00% | +669,350+3.0% | Added |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −1,412,550−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −1,226,400−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −390,000−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −344,042−100.0% | Sold out |
| Seven Eight Capital, LP | 0 | $0 | 0.00% | −319,502−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −227,000−100.0% | Sold out |
| Capital Fund Management S.A. | 0 | $0 | 0.00% | −219,973−100.0% | Sold out |
| Capula Management Ltd | 0 | $0 | 0.00% | −140,060−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −139,014−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −128,541−100.0% | Sold out |
| Carlson Capital L P | 0 | $0 | 0.00% | −108,280−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −98,663−100.0% | Sold out |
| Arctis Global LLC | 0 | $0 | 0.00% | −87,331−100.0% | Sold out |
| Edgestream Partners, L.P. | 0 | $0 | 0.00% | −65,184−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −44,367−100.0% | Sold out |
| Kettle Hill Capital Management, LLC | 0 | $0 | 0.00% | −38,474−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −35,011−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −26,791−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −26,337−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −22,908−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −19,819−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −18,863−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −18,500−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −13,500−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −10,318−100.0% | Sold out |
| Sandia Investment Management LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −7,786−100.0% | Sold out |
| Annandale Capital, LLC | 0 | $0 | 0.00% | −7,000−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −2,600−100.0% | Sold out |
| Pathway Financial Advisers, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Cary Street Partner Investment Advisory LLC | 0 | $0 | 0.00% | −1,800−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Macroview Investment Management LLC | 0 | $0 | 0.00% | −646−100.0% | Sold out |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −485−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −63−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |
| First Republic Investment Management, Inc. | – | – | – | – | Not filed |
| Pathstone Family Office, LLC | – | – | – | – | Not filed |